Angiotensin II and Phosphoinositide Signaling Pathway

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/20

flashcard set

Earn XP

Description and Tags

Vocabulary practice flashcards covering the components, mechanisms, comparative pathways, and experimental perturbations of the angiotensin II phosphoinositide signaling pathway.

21 Terms

1
New cards

Angiotensin II

The hormone that uses the phosphoinositide pathway to cause vasoconstriction, which regulates (raises) blood pressure.

2
New cards

Vascular smooth muscle cells

The cell type in blood vessel walls where the angiotensin II pathway acts.

3
New cards

Phosphatidylinositol 4,5-bisphosphate (PIP2PIP_2)

A phospholipid located in the plasma membrane that is cut by phospholipase C into the second messengers IP3IP_3 and DAG.

4
New cards

Phospholipase C

The enzyme activated through a G protein upon hormone receptor binding that cuts PIP2PIP_2 into IP3IP_3 and DAG.

5
New cards

Inositol 1,4,5-trisphosphate (IP3IP_3)

A second messenger released into the cytoplasm that diffuses to the smooth ER and opens Ca2+Ca^{2+} channels in the ER membrane.

6
New cards

Diacylglycerol (DAG)

A second messenger that remains in the plasma membrane after cleavage of PIP2PIP_2 and helps activate protein kinase C.

7
New cards

Protein kinase C (PKC)

A kinase activated by DAG in the membrane together with Ca2+Ca^{2+} released by IP3IP_3, which causes vasoconstriction (smooth muscle contraction).

8
New cards

Vasoconstriction

Smooth muscle contraction in blood vessel walls caused by PKC activation that regulates (raises) blood pressure.

9
New cards

Smooth endoplasmic reticulum

The organelle whose lumen stores Ca2+Ca^{2+} at high concentration before release by IP3IP_3.

10
New cards

IP3IP_3-gated Ca2+Ca^{2+} release

A process of passive transport (facilitated diffusion) where Ca2+Ca^{2+} flows down its concentration gradient through a ligand-gated channel without ATP.

11
New cards

Protein kinase A (PKA)

The kinase associated with cAMP in the epinephrine signaling pathway (remembered by 'A' for AMP).

12
New cards

Epinephrine pathway

A GPCR signaling pathway that proceeds through adenylyl cyclase →\rightarrow cAMP →\rightarrow PKA.

13
New cards

Angiotensin II pathway

A GPCR signaling pathway that proceeds through phospholipase C →\rightarrow IP3IP_3 + DAG (+ Ca2+Ca^{2+}) →\rightarrow PKC.

14
New cards

Phospholipase C inhibition

A condition in which PIP2PIP_2 is not cleaved, preventing the production of IP3IP_3 and DAG, blocking Ca2+Ca^{2+} release, leaving PKC inactive, and preventing vasoconstriction.

15
New cards

ER Ca2+Ca^{2+} channel binding defect

A defect preventing IP3IP_3 from binding its channel; receptor activation, phospholipase C, and IP3IP_3/DAG production still occur, but Ca2+Ca^{2+} release fails, preventing full PKC activation and vasoconstriction.

16
New cards

PKC inhibitor

A compound under which upstream steps function normally (IP3IP_3 and Ca2+Ca^{2+} levels still rise), but blood vessels do not constrict because PKC cannot act.

17
New cards

Angiotensin II receptor blocker

A drug that causes blood pressure to drop by halting receptor activation, thereby preventing the phospholipase C →\rightarrow IP3IP_3/DAG →\rightarrow Ca2+Ca^{2+} →\rightarrow PKC cascade so vessels constrict less.

18
New cards

G protein

The signaling protein that is activated immediately following angiotensin II receptor binding and subsequently activates phospholipase C.

19
New cards

Cytoplasm

The intracellular fluid compartment where IP3IP_3 is released after cleavage and into which Ca2+Ca^{2+} flows from the ER lumen.

20
New cards

Ligand-gated Ca2+Ca^{2+} channel

The membrane channel on the smooth ER that opens when bound by the ligand IP3IP_3, allowing passive diffusion of calcium ions.

21
New cards

Second messengers

Intracellular signaling molecules produced during signal transduction, specifically IP3IP_3 and DAG in the phosphoinositide pathway, and cAMP in the epinephrine pathway.